Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...9899100101102103104105106107108...10651066»
  • ||||||||||  dexamethasone / Generic mfg., prednisone / Generic mfg., hydrocortisone / Generic mfg.
    Journal:  Comparing the Effectiveness of Glucocorticoids in Preventing Hypertrophic Scar Diagnosis in Burn Patients. (Pubmed Central) -  Nov 29, 2023   
    Methylprednisolone was associated with reduced hypertrophic scar diagnosis in burn patients independent of TBSA burn. While glucocorticoids are one of the mainstay treatments for hypertrophic scarring, further studies are needed to determine early therapeutic interventions that will reduce the potential for hypertrophic scar development in burn patients.
  • ||||||||||  fluocinolone acetonide / Generic mfg.
    Journal:  The Effects of Lumbricus rubellus Extract on Staphylococcus aureus Colonization and IL-31 Levels in Children with Atopic Dermatitis. (Pubmed Central) -  Nov 29, 2023   
    AD patients aged 8-16 who had a Scoring Atopic Dermatitis (SCORAD) index > 25, with total IgE serum level > 100 IU/mL, and had healthy weight were randomly assigned into two groups: one received fluocinolone acetonide 0.025% and placebo (control group) and one received fluocinolone acetonide 0.025% combined with L. rubellus extract (Vermint) (intervention group)...Moreover, fourteen AD patients in the intervention group showed an improvement in the SCORAD index of more than 35% (p = 0.057). L. rubellus extract significantly decreases S. aureus colonization and the IL-31 level in AD patients, suggesting its potential as an adjuvant therapy for children with AD.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  BRIP1 and BRIP2 maintain root meristem by affecting auxin-mediated regulation. (Pubmed Central) -  Nov 29, 2023   
    Using a dexamethasone (DEX)-inducible PLT2 transgenic line, we showed that acute overexpression of PLT2 partially rescues root meristem defects of brip1 brip2, suggesting that BRIP1 and BRIP2 act in part through the PLT1/2 pathway. Taken together, our results identify the critical role and the underlying mechanism of BRIP1/2 in maintaining the development of root meristem through the regulation of auxin output and expression of PLTs.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Preparation, identification, activity prediction, and protective effects on IR-HepG2 cells of five novel DPP-IV inhibitory peptides from protein hydrolysate of skipjack tuna dark muscles. (Pubmed Central) -  Nov 29, 2023   
    The above five peptides were proved to effectively promote glucose consumption in the insulin resistant-HepG2 (IR-HepG2) cell model considering that the glucose consumption rates of APP, PPP, DPLL, EAVP and EAIP treatment groups are all more than twice that of the dexamethasone group...These findings demonstrated that skipjack tuna dark muscle is a potential DPP-IV inhibitory peptide source, and five DPP-IV inhibitory peptides from its hydrolysate may exert potent anti-diabetic activity. In comparison, PPP may be the most potential active ingredient for healthy food against type 2 diabetes mellitus in the five screened peptides considering synthetically the DPP-IV inhibitory rate, bioavailability and synthesis cost.
  • ||||||||||  prednisolone / Generic mfg.
    Trial completion date, Trial primary completion date:  High-TeC: Nasal High-Flow in COPD (clinicaltrials.gov) -  Nov 29, 2023   
    P=N/A,  N=136, Recruiting, 
    Early lesions with minimal chronicity showed an excellent response to budesonide. Trial completion date: Jul 2023 --> Dec 2025 | Trial primary completion date: May 2023 --> Oct 2025
  • ||||||||||  Jakafi (ruxolitinib) / Incyte
    Trial completion, Trial completion date, Combination therapy:  First Line Therapy for High Risk Acute GVHD (clinicaltrials.gov) -  Nov 29, 2023   
    P2,  N=198, Completed, 
    Trial completion date: Jul 2023 --> Dec 2025 | Trial primary completion date: May 2023 --> Oct 2025 Recruiting --> Completed | Trial completion date: Dec 2025 --> Jun 2023
  • ||||||||||  methylprednisolone oral / Generic mfg., dexamethasone injection / Generic mfg.
    Enrollment open:  Methylprednisolone Taper, Lower Extremity (clinicaltrials.gov) -  Nov 29, 2023   
    P4,  N=200, Recruiting, 
    Initiation date: Oct 2023 --> Jan 2024 Not yet recruiting --> Recruiting
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
    Journal:  Rituximab-bortezomib-dexamethasone induce high response rates in iMCD in clinical practice. (Pubmed Central) -  Nov 29, 2023   
    Collectively, these findings demonstrated that the RVD regimen may be a promising treatment option for patients with iMCD. It was a safe and effective approach that resulted in lasting responses without the need for ongoing maintenance therapy.
  • ||||||||||  Abecma (idecabtagene vicleucel) / BMS, 2seventy bio, mezigdomide (CC-92480) / BMS
    Trial completion date, Trial primary completion date:  Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma (clinicaltrials.gov) -  Nov 29, 2023   
    P1,  N=15, Recruiting, 
    It was a safe and effective approach that resulted in lasting responses without the need for ongoing maintenance therapy. Trial completion date: Jul 2025 --> Mar 2026 | Trial primary completion date: Jul 2025 --> Mar 2026
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Impact of overnight 1 (Pubmed Central) -  Nov 29, 2023   
    Flow-mediated vasodilation (FMD) and nitroglycerine-induced vasodilation (NID) were measured to assess vascular function in 22 patients with NFA who had hypertension and/or diabetes mellitus (DM) and 272 patients without adrenal incidentalomas who had hypertension and/or DM (control patients with hypertension and/or DM). The overnight 1
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Four New Pentacyclic Triterpene Glycosides Isolated from the Fruits of  (Pubmed Central) -  Nov 28, 2023   
    Their structures were determined to be uncargenin C 28-O-?-L-rhamnopyranosyl-(1?2)-?-D-glucopyranosyl ester (1), 3-O-?-D-glucopyranosyluncargenin C 28-O-?-L-rhamnopyranosyl-(1?2)-?-D-glucopyranosyl ester (2), 3-O-?-D-glucopyranosyl-(1?6)-?-D-glucopyranosyl-6?,23-dihydroxyursolic acid 28-O-?-L-rhamnopyranosyl-(1?2)-?-D-glucopyranosyl ester (3), 3-O-?-D-glucopyranosyl-(1?2)-?-D-glucopyranosylasiatic acid 28-O-?-L-rhamnopyranosyl-(1?2)-?-D-glucopyranosyl ester (4), asiatic acid (5), 2?,3?,23-trihydroxyolean-11,13(18)-dien-28-oic acid (6), arjunolic acid (7), 6?-hydroxyarjunolic acid (8), and actinidic acid (9) based on analyses of their HR-ESI-MS, 1D and 2D NMR spectra. All the isolates showed significantly NO production inhibition in LPS-activated RAW264.7 cells with the IC50 values ranging from 18.79 to 37.57 ?M, compared to that of the positive control compound, dexamethasone, which showed IC50 value of 14.05 ?M.
  • ||||||||||  Tecvayli (teclistamab-cqyv) / Genmab, J&J
    Enrollment change, Trial completion date, Trial primary completion date, Combination therapy:  GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 (clinicaltrials.gov) -  Nov 28, 2023   
    P2,  N=70, Recruiting, 
    CRD42022362924. N=50 --> 70 | Trial completion date: May 2027 --> Oct 2027 | Trial primary completion date: May 2026 --> Oct 2026
  • ||||||||||  dexamethasone injection / Generic mfg., ropivacaine / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Effect of Perineural Dexamethasone on the Duration of Popliteal Nerve Block for Anesthesia After Ankle Surgery (clinicaltrials.gov) -  Nov 28, 2023   
    P4,  N=84, Completed, 
    N=50 --> 70 | Trial completion date: May 2027 --> Oct 2027 | Trial primary completion date: May 2026 --> Oct 2026 Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Nov 2023 | Trial primary completion date: Dec 2022 --> Nov 2023
  • ||||||||||  Adcetris (brentuximab vedotin) / Takeda, Pfizer
    Trial primary completion date:  B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma (clinicaltrials.gov) -  Nov 27, 2023   
    P1/2,  N=34, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Nov 2023 | Trial primary completion date: Dec 2022 --> Nov 2023 Trial primary completion date: Aug 2023 --> Dec 2023
  • ||||||||||  Budenofalk (budesonide gastro-resistant) / Dr Falk
    Journal:  An open-label study evaluating the safety and efficacy of budesonide in patients with IgA nephropathy at high risk of progression. (Pubmed Central) -  Nov 27, 2023   
    We sought to evaluate the efficacy and safety of budesonide (Budenofalk) in the treatment of patients with IgA Nephropathy...Budesonide was well-tolerated, and treatment emergent adverse events were mostly mild in severity and reversible. Budesonide was effective in the treatment of patients with IgAN at high-risk of progression in terms of reducing proteinuria and preserving renal function over 36
  • ||||||||||  dexamethasone / Generic mfg.
    Review, Journal:  Estrogen dysregulation, intraocular pressure, and glaucoma risk. (Pubmed Central) -  Nov 27, 2023   
    Glucocorticoids such as dexamethasone have long been known to elevate IOP and lead to glaucoma...As a result, the estrogen signaling pathway may offer a therapeutic target for both IOP control and neuroprotection. This review examines the evidence for a relationship between estrogen and IOP and explores the possible mechanisms by which estrogen maintains IOP homeostasis.
  • ||||||||||  dexamethasone / Generic mfg., dexmedetomidine / Generic mfg.
    Review, Journal:  Peripheral nerve block adjuncts: which medication to choose? A narrative review of the current literature. (Pubmed Central) -  Nov 27, 2023   
    To date, the most commonly used adjuncts, and ones with the most robust scientific efficacy are, dexamethasone, dexmedetomidine and buprenorphine. This narrative review will discuss several classes of local anesthetic adjuncts and provide evidence for the clinical efficacy and side effect profile of the most commonly studied medications.
  • ||||||||||  dexamethasone sustained-release (TLC599) / Taiwan Liposome Company, Endo
    Enrollment closed, Trial completion date:  Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole (clinicaltrials.gov) -  Nov 27, 2023   
    P1,  N=2, Active, not recruiting, 
    This narrative review will discuss several classes of local anesthetic adjuncts and provide evidence for the clinical efficacy and side effect profile of the most commonly studied medications. Unknown status --> Active, not recruiting | Trial completion date: Sep 2020 --> Sep 2024
  • ||||||||||  dexamethasone / Generic mfg.
    Retrospective data, Review, Journal:  Effect of dexamethasone dose on outcomes in acute COVID-19 disease: a systematic review and meta-analysis. (Pubmed Central) -  Nov 27, 2023   
    It provides a reasonable scientific basis for understanding of the HMs originated from multi-plant sources for the same clinical application. The mortality of patients with acute COVID-19 receiving high-dose dexamethasone is similar to patients receiving low-dose dexamethasone, although high-dose dexamethasone is associated with an increased risk of hyperglycaemia.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Xuanbai Chengqi Decoction alleviates acute lung injury by inhibiting NLRP3 inflammasome. (Pubmed Central) -  Nov 27, 2023   
    The mortality of patients with acute COVID-19 receiving high-dose dexamethasone is similar to patients receiving low-dose dexamethasone, although high-dose dexamethasone is associated with an increased risk of hyperglycaemia. The therapeutic mechanism of XCD in ALI treatment may involve alleviating inflammatory responses in lung tissues by inhibiting the activation of the NLRP3 inflammasome-mediated pyroptosis in macrophages.
  • ||||||||||  Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
    Clinical data, Journal:  Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study. (Pubmed Central) -  Nov 27, 2023   
    P3
    The therapeutic mechanism of XCD in ALI treatment may involve alleviating inflammatory responses in lung tissues by inhibiting the activation of the NLRP3 inflammasome-mediated pyroptosis in macrophages. Appropriate dose reductions in response to AEs of the 100 mg selinexor starting dose in the BOSTON study were associated with improved efficacy, reduced AE rates and improved QoL.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Dendrobium offificinale polysaccharides prevents glucocorticoids-induced osteoporosis by destabilizing KEAP1-NRF2 interaction. (Pubmed Central) -  Nov 27, 2023   
    Here, we sought to investigate the impacts of D. officinale polysaccharides (DOP), the main active constituents of D. officinale, on GIOP in vivo models and dexamethasone (DEX)-treated osteoblast lineage cells...Taken together, these results illuminate that DOP stimulates osteogenesis in the presence of DEX by destabilizing the Nrf2/Keap1 interaction. These findings suggest that DOP may serve as a novel drug against osteoporosis caused by glucocorticoids.
  • ||||||||||  Journal:  Multiple Myeloma-Associated Leukocytoclastic Vasculitis Mimicking Autoimmune Vasculitis. (Pubmed Central) -  Nov 27, 2023   
    Although leukocytoclastic vasculitis is commonly associated with immune-mediated systemic vasculitis, cutaneous leukocytoclastic vasculitis may be observed in case of malignancy. Monoclonal gammopathies should be considered in cases of leukocytoclastic vasculitis associated with renal and blood disorders.Differential diagnosis: immunoglobulin A vasculitis, microscopic polyarteritis, granulomatosis with polyangiitis, and eosinophilic granulomatosis with polyangiitis.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Sex Differences in Long-term Outcome of Prenatal Exposure to Excess Glucocorticoids-Implications for Development of Psychiatric Disorders. (Pubmed Central) -  Nov 27, 2023   
    The aim of the present study was to investigate the long-term effects of in utero exposure to the synthetic GC analog dexamethasone (Dex) in adult female offspring...We selected a set of candidate genes matching the behaviour alterations and found consistent differential regulation for?~?73% of tested genes in SCN and hippocampus tissue samples. Taken together, our data highlight sex differences in the outcome of prenatal exposure to excess GC in adult mice: in contrast to depression-like behaviour in males, the phenotype in females, defined by behaviour and differential gene expression, is consistent with ADHD models.